Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 14

1.

Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Johnson DS, Weerapana E, Cravatt BF.

Future Med Chem. 2010 Jun;2(6):949-64.

2.

Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes.

Bachovchin DA, Brown SJ, Rosen H, Cravatt BF.

Nat Biotechnol. 2009 Apr;27(4):387-94. doi: 10.1038/nbt.1531. Epub 2009 Mar 29. Erratum in: Nat Biotechnol. 2009 May;27(5):485.

3.

Crystal structure of human retinoblastoma binding protein 9.

Vorobiev SM, Su M, Seetharaman J, Huang YJ, Chen CX, Maglaqui M, Janjua H, Proudfoot M, Yakunin A, Xiao R, Acton TB, Montelione GT, Tong L.

Proteins. 2009 Feb 1;74(2):526-9. doi: 10.1002/prot.22278. No abstract available.

4.

Novel retinoblastoma binding protein RBBP9 modulates sex-specific radiation responses in vivo.

Cassie S, Koturbash I, Hudson D, Baker M, Ilnytskyy Y, Rodriguez-Juarez R, Weber E, Kovalchuk O.

Carcinogenesis. 2006 Mar;27(3):465-74. Epub 2005 Nov 4.

PMID:
16272168
5.

Mechanistic basis of enzyme-targeted drugs.

Robertson JG.

Biochemistry. 2005 Apr 19;44(15):5561-71. Review. Erratum in: Biochemistry. 2005 Jun 21;44(24):8918.

PMID:
15823014
6.

Discovering potent and selective reversible inhibitors of enzymes in complex proteomes.

Leung D, Hardouin C, Boger DL, Cravatt BF.

Nat Biotechnol. 2003 Jun;21(6):687-91. Epub 2003 May 12.

PMID:
12740587
7.

Cloning and expression of a novel retinoblastoma binding protein cDNA, RBBP10.

Chen JZ, Yang QS, Wang S, Meng XF, Ying K, Xie Y, Ma YM.

Biochem Genet. 2002 Aug;40(7-8):273-82.

PMID:
12296629
8.

Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness.

Jessani N, Liu Y, Humphrey M, Cravatt BF.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10335-40. Epub 2002 Jul 29.

9.

Prediction of intestinal permeability.

Egan WJ, Lauri G.

Adv Drug Deliv Rev. 2002 Mar 31;54(3):273-89. Review.

PMID:
11922948
10.

Prediction of drug absorption using multivariate statistics.

Egan WJ, Merz KM Jr, Baldwin JJ.

J Med Chem. 2000 Oct 19;43(21):3867-77.

PMID:
11052792
11.

Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.

Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL.

Cancer Chemother Pharmacol. 2000;45(3):231-8.

PMID:
10663641
12.

Assignment of the Bog gene (RBBP9) to syntenic regions of mouse chromosome 2G1-H1 and human chromosome 20p11.2 by fluorescence in situ hybridization.

Woitach JT, Hong R, Keck CL, Zimonjic DB, Popescu NC, Thorgeirsson SS.

Cytogenet Cell Genet. 1999;85(3-4):252-3. No abstract available.

PMID:
10449909
13.

A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability.

Woitach JT, Zhang M, Niu CH, Thorgeirsson SS.

Nat Genet. 1998 Aug;19(4):371-4.

PMID:
9697699
14.

E2F: a link between the Rb tumor suppressor protein and viral oncoproteins.

Nevins JR.

Science. 1992 Oct 16;258(5081):424-9.

PMID:
1411535

Supplemental Content

Support Center